Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Breast Cancer
•
Radiation Oncology
Would you consider partial breast irradiation in patients who otherwise meet PBI guidelines who have a pathogenic variant of CHEK2 or other moderate penetrance gene?
Related Questions
What is the appropriate approach to manage a patient with triple-negative, locally advanced breast cancer (LN+) who progresses on neoadjuvant chemo-immunotherapy (KEYNOTE-522 regimen)?
Are there additional risks associated with PMRT for a patient with prior lympho-venous bypass surgery?
Can a patient receiving post-mastectomy radiation therapy be treated concurrently with total body UVA or UVB light therapy for psoriasis?
In a clinically node negative early stage breast cancer patient who underwent neoadjuvant systemic therapy, would surgical finding of fibrosis suspicious for treatment effect in sentinel nodes impact your RT decision?
Do you offer APBI to patients who do not have surgical clips but a visible seroma?
Is Behcet's disease a contraindication to breast conserving therapy?
In the post-mastectomy setting, are there situations where only the regional nodes or targeted nodal basis are covered?
How would you manage a patient with micrometastatic node positive tumor post mastectomy (no neoadjuvant chemotherapy)?
Would you recommend MRI post surgery and pre-irradiation for patients with extensive DCIS and close margins and how would it impact your management?
What are your top takeaways from SABCS 2023?
